Daniel Antonio de Luis1, Gonzalo Diaz Soto2, Olatz Izaola2, Enrique Romero2. 1. Center of Investigation of endocrinology and Nutrition, Medicine School, Department of Endocrinology and Nutrition Hospital Clinico Universitario, University of Valladolid, Valladolid Spain. Electronic address: dadluis@yahoo.es. 2. Center of Investigation of endocrinology and Nutrition, Medicine School, Department of Endocrinology and Nutrition Hospital Clinico Universitario, University of Valladolid, Valladolid Spain.
Abstract
BACKGROUND: A polymorphism of GLP-1 R (rs6923761) has potential implications in weight loss and metabolic control. We decide to investigate the role of this polymorphism on metabolic changes and weight loss secondary to treatment with liraglutide. MATERIAL AND METHODS: A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed. RESULTS: Fifty one patients (56.7%) had the genotype GG and 39 (43.3%) patients; GA (30 patients, 33.3%) or AA (9 patients, 10%) (A allele carriers). In patients with both genotypes, body mass index (BMI), weight and fat decreased. The proportion of the mentioned reductions was higher in the variant allele carriers; BMI (-0.59±2.5kg/m(2) vs. -1.69±3.9kg/m(2); P<0.05), weight (-2.78±2.8kg vs. -4.52±4.6kg; P<0.05) and fat mass (-0.59±2.5kg vs. -1.69±3.9kg; P<0.05). Weight reduction after liraglutide treatment was greater in the A-allele carriers by 2.9kg (95% CI: 0.27-5.64). The decrease of basal glucose, HOMA-R and HbA1c was similar in both genotypes. CONCLUSION: Our data showed better anthropometric parameters in overweight diabetic subjects with the variant allele (A) of rs6923761 GLP-1 R polymorphism. A allele carriers had a greater decrease in weight and fat mass after treatment with liraglutide. The present study is a preliminary observation, and its results need to be replicated with a higher number of patients in different populations.
BACKGROUND: A polymorphism of GLP-1 R (rs6923761) has potential implications in weight loss and metabolic control. We decide to investigate the role of this polymorphism on metabolic changes and weight loss secondary to treatment with liraglutide. MATERIAL AND METHODS: A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed. RESULTS: Fifty one patients (56.7%) had the genotype GG and 39 (43.3%) patients; GA (30 patients, 33.3%) or AA (9 patients, 10%) (A allele carriers). In patients with both genotypes, body mass index (BMI), weight and fat decreased. The proportion of the mentioned reductions was higher in the variant allele carriers; BMI (-0.59±2.5kg/m(2) vs. -1.69±3.9kg/m(2); P<0.05), weight (-2.78±2.8kg vs. -4.52±4.6kg; P<0.05) and fat mass (-0.59±2.5kg vs. -1.69±3.9kg; P<0.05). Weight reduction after liraglutide treatment was greater in the A-allele carriers by 2.9kg (95% CI: 0.27-5.64). The decrease of basal glucose, HOMA-R and HbA1c was similar in both genotypes. CONCLUSION: Our data showed better anthropometric parameters in overweight diabetic subjects with the variant allele (A) of rs6923761GLP-1 R polymorphism. A allele carriers had a greater decrease in weight and fat mass after treatment with liraglutide. The present study is a preliminary observation, and its results need to be replicated with a higher number of patients in different populations.
Authors: M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld Journal: Pharmacogenomics J Date: 2016-07-19 Impact factor: 3.550
Authors: Daniel Maselli; Jessica Atieh; Matthew M Clark; Deborah Eckert; Ann Taylor; Paula Carlson; Duane D Burton; Irene Busciglio; W Scott Harmsen; Adrian Vella; Andres Acosta; Michael Camilleri Journal: Obesity (Silver Spring) Date: 2022-08 Impact factor: 9.298
Authors: V Chedid; P Vijayvargiya; P Carlson; K Van Malderen; A Acosta; A Zinsmeister; M Camilleri Journal: Neurogastroenterol Motil Date: 2018-02-28 Impact factor: 3.598
Authors: Mona Mashayekhi; Jessica R Wilson; Scott Jafarian-Kerman; Hui Nian; Chang Yu; Megan M Shuey; James M Luther; Nancy J Brown Journal: Diabetes Obes Metab Date: 2020-10-22 Impact factor: 6.408